ストックスクリーナーアプリを入手
17.72
2.84%
0.49
アフターアワーズ：
17.85
0.13
+0.73%
前日終値:
$17.23
開ける：
$17.44
24時間の取引高:
1.87M
Relative Volume:
0.67
時価総額：
$2.27B
収益：
$1.00B
当期純損益:
$22.39M
株価収益率:
143.48
EPS:
0.1235
ネットキャッシュフロー:
$45.01M
1週間 パフォーマンス:
-0.95%
1か月 パフォーマンス:
-17.27%
6か月 パフォーマンス:
-20.25%
1年 パフォーマンス:
-25.42%
1日の値動き範囲:
$17.39
$17.96
1週間の範囲:
$16.84
$18.09
52週間の値動き範囲:
$16.10
$30.48
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
名前
Apellis Pharmaceuticals Inc
セクター
電話
617-977-5700
住所
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
17.72 | 2.20B | 1.00B | 22.39M | 45.01M | 0.1235 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-13 | 開始されました | Roth Capital | Buy |
| 2026-01-28 | 開始されました | Barclays | Equal Weight |
| 2026-01-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-11-06 | 開始されました | Wolfe Research | Peer Perform |
| 2025-10-15 | 開始されました | Wells Fargo | Overweight |
| 2025-09-26 | ダウングレード | Goldman | Neutral → Sell |
| 2025-05-09 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-05-09 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-17 | ダウングレード | Goldman | Buy → Neutral |
| 2024-11-21 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-16 | 開始されました | William Blair | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Neutral |
| 2024-02-05 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-02 | 開始されました | Mizuho | Neutral |
| 2023-10-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-15 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 繰り返されました | Citigroup | Buy |
| 2023-08-03 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-08-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-19 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-17 | 再開されました | Stifel | Buy |
| 2022-04-14 | ダウングレード | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-09-10 | 繰り返されました | Credit Suisse | Neutral |
| 2021-09-10 | 繰り返されました | Needham | Buy |
| 2021-09-10 | 繰り返されました | Oppenheimer | Outperform |
| 2021-09-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-08-19 | 開始されました | Jefferies | Buy |
| 2021-08-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2020-11-19 | 開始されました | Needham | Buy |
| 2020-09-01 | 開始されました | Stifel | Buy |
| 2020-07-20 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Neutral |
| 2020-04-01 | 開始されました | Raymond James | Strong Buy |
| 2020-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-11 | アップグレード | Wedbush | Underperform → Neutral |
| 2020-01-07 | 開始されました | SVB Leerink | Mkt Perform |
| 2019-12-19 | 開始されました | BofA/Merrill | Buy |
| 2019-11-22 | 開始されました | Wedbush | Underperform |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-08-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-07-30 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-04-12 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Apellis Pharmaceuticals Inc (APLS) 最新ニュース
Bear Alert: Will Apellis Pharmaceuticals Inc announce a stock splitWeekly Stock Analysis & Real-Time Market Trend Scan - baoquankhu1.vn
APLS SEC FilingsApellis Pharmace 10-K, 10-Q, 8-K Forms - Stock Titan
Apellis Pharmaceuticals, Inc. (APLS) surpasses Q4 earnings and revenue estimates - MSN
Apellis wins new buy at Roth on Syfovre prospects - MSN
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story - The Globe and Mail
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story - The Motley Fool
Apellis Pharmaceuticals, Inc. $APLS Holdings Cut by Hudson Bay Capital Management LP - MarketBeat
Complement 3 Glomerulopathy Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma - Barchart.com
BofA upgrades Apellis (APLS) to buy citing rapid Empaveli adoption and underappreciated kidney disease market potential - MSN
APLS: Cantor Fitzgerald Lowers Price Target While Maintaining Ov - GuruFocus
Cantor Fitzgerald Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Price-Driven Insight from (APLS) for Rule-Based Strategy - Stock Traders Daily
Bank of Nova Scotia Acquires 861,413 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Does Apellis Pharmaceuticals' (APLS) New Board Member Reveal a Deeper R&D Commercialization Strategy Shift? - simplywall.st
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by HighVista Strategies LLC - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Apellis Pharmaceuticals, Inc.Common Stock (NQ: APLS - The Chronicle-Journal
Assessing Apellis Pharmaceuticals (APLS) Valuation After Weaker Returns And EMPAVELI Label Expansion - Yahoo Finance
Integral Health Asset Management LLC Purchases Shares of 250,000 Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (APLS) Receives Buy Rating Amid Growth P - GuruFocus
Analysts’ Top Healthcare Picks: Apellis Pharmaceuticals (APLS), Argenx Se (ARGX) - The Globe and Mail
Apellis (NASDAQ: APLS) CEO gifts 129,738 shares via family trusts - Stock Titan
APLS: Roth Capital Initiates Coverage with 'Buy' Rating at $31.0 - GuruFocus
Apellis stock wins new Buy at Roth on Syfovre (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Roth Mkm - MarketBeat
Roth Capital initiates coverage of Apellis Pharmaceuticals (APLS) with buy recommendation - MSN
Here is Why JPMorgan is Overweight on Apellis Pharma (APLS) - Finviz
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
How Apellis Adding Ex-Pfizer R&D Chief Mikael Dolsten to Its Board Will Impact Apellis (APLS) Investors - simplywall.st
Rhenman & Partners Asset Management AB Has $5.26 Million Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Balances Growth With Revenue Headwinds - The Globe and Mail
Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN
Apellis Adds Ex Pfizer R&D Chief To Board As Growth Plans Evolve - Sahm
Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS) - The Globe and Mail
(APLS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
JP Morgan Raises Price Target for APLS, Maintains Overweight Rat - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $37.00 at JPMorgan Chase & Co. - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $20.00 at Mizuho - MarketBeat
APLS: Mizuho Maintains Rating, Raises Price Target | APLS Stock News - GuruFocus
Assessing Apellis Pharmaceuticals: Insights From 11 Financial Analysts - Benzinga
APLS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Update Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn
Apellis Pharmaceuticals (APLS) director receives new stock options and RSUs - Stock Titan
Apellis (APLS) director Mikael Dolsten submits initial Form 3 insider filing - Stock Titan
Apellis Pharmaceuticals (APLS) Stock Analysis: Exploring a 62.73% Upside Potential in Biotech - DirectorsTalk Interviews
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf. - MarketBeat
Apellis adds former Pfizer research chief to board - Investing.com
Apellis Pharmaceuticals appoints Mikael Dolsten to board of directors - Investing.com Australia
Apellis Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Vanguard Group Inc. - MarketBeat
Apellis Pharmaceuticals Adds Mikael Dolsten to Board - TipRanks
Apellis Pharmaceuticals Inc (APLS) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):